Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Evenamide

Alternative Names: evenamide, NW-3509, NW3509, NW 3509
Clinical Status: Active
Latest Update: 2025-07-09
Latest Update Note: News Article

Product Description

Newron is developing Evenamide as a treatment for schizophrenia. (Sourced from: https://www.newron.com/news-and-media/regulatory-news/newron-announces-striking-six-month-interim-results-its-exploratory)

Mechanisms of Action: Voltage-Gated Sodium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Newron
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Bipolar Disorder|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
2020-006062-36

P3

Completed

Schizophrenia

2024-11-06

2025-07-08

Treatments
Evenamide_020

P3

Completed

Bipolar Disorder|Schizophrenia

2024-02-10

2025-05-15

Treatments

Recent News Events

Date

Type

Title

07/09/2025

News Article

 Edison Issues Report on Newron Pharmaceuticals (NWRN)

05/12/2025

News Article

 Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)

04/01/2025

News Article

 Newron Presents 2024 Financial Results and Provides 2025 Outlook

03/11/2025

News Article

 Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference

02/01/2024

PubMed

 Evenamide: A Potential Pharmacotherapeutic Alternative for Treatment-Resistant Schizophrenia.

08/29/2023

PubMed

 Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.

02/28/2023

PubMed

 The Future of Schizophrenia Psychopharmacotherapy: More Antipsychotic Atypicality? Guess So!

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions